Πρωτεύουσες καρτέλες
Ο κατάλογος των δημοσιεύσεων είναι ενδεικτικός και μπορεί να μην περιλαμβάνει το σύνολο των δημοσιεύσεων.
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Clinical Drug Investigation. 3831184061314132015410373121437191919154637191436(511Suppl 2518942221193773988), 417 - 426.
(2018).
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.
Heart Failure Reviews. 377 - 388.
(2018).
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece..
Clin Drug Investig. 38(5), 417-426.
(2018).
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors..
Heart Fail Rev. 23(3), 377-388.
(2018).
The beta-cell death in long-term type 2 diabetes mellitus: never say never again..
Minerva Endocrinol.
(2018).
Metabolic syndrome, independent of its components, affects adversely cardiovascular morbidity in essential hypertensives..
Atherosclerosis. 244, 66-72.
(2016).
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors..
Hormones (Athens). 15(1), 8-14.
(2016).
Hypoglycaemia requiring medical assistance in patients with diabetes: a prospective multicentre survey in tertiary hospitals..
Diabetes Metab. 41(2), 126-31.
(2015).
Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide..
J Diabetes Res. 2014, 304032.
(2014).
Diabetes treatment in patients with renal disease: Is the landscape clear enough?.
World J Diabetes. 5(5), 651-8.
(2014).
Metabolic effects of renal denervation..
Curr Clin Pharmacol. 8(3), 206-11.
(2013).
Prevalence of overweight and abdominal obesity in Greek children 6-12 years old: Results from the National Epidemiological Survey..
Hippokratia. 15(1), 48-53.
(2011).